Mosunetuzumab and Polatuzumab Vedotin as First-line Treatment for Large B Cell Lymphoma in Older Unfit or Frail Patients. (PubMed, Blood) - Oct 6, 2026 - P1/2 | "This geriatric assessment-guided treatment demonstrated durable efficacy and may represent a potential first-line treatment option for carefully selected unfit or frail patients with newly diagnosed DLBCL. Trial registration: #NCT03677154."
Journal • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin's Lymphoma • Novel Coronavirus Disease • Oncology
|
|
Abraham Avigdor; Adam J Olszewski; Antonia Rodriguez Izquierdo; Avrita Singh; Chezi Ganzel; Connie Lee Batlevi; Dariusz Woszczyk; Gila Sellam; Herbert A Eradat; Ho-Jin Shin; Juan Miguel Bergua Burgues; Jue Wang; Mariana Bastos-Oreiro; Martin Janousek; Matthew S McKinney; Mayur S Narkhede; Michael C Wei; Neta Goldschmidt; Netanel A Horowitz; Seung Tae Lee; Tae Min Kim; Wahib Ead; Wojciech Jurczak; Won Seog Kim; Youngwoo Jeon
|